先为达生物先颐达获批 用于成人2型糖尿病血糖控制

Group 1 - The core point of the article is that Xianweida Biotechnology Co., Ltd. announced the approval of its drug, Xianyi Da® (Enogratide injection), by the National Medical Products Administration (NMPA) for blood sugar control in adult patients with type 2 diabetes [1][2] - The number of diabetes patients in China is projected to reach approximately 148 million by 2024, indicating a growing market for diabetes treatment [1] - The treatment paradigm for diabetes is evolving from mere blood sugar control to a comprehensive approach that includes reducing cardiovascular risks and protecting organ function [1] Group 2 - Enogratide injection is a cAMP biased GLP-1 receptor agonist, which differs from non-biased GLP-1 receptor agonists by preferentially activating the cAMP signaling pathway while minimizing β-arrestin recruitment, thus enhancing clinical efficacy and metabolic benefits [1][2] - The approval of Enogratide is based on two pivotal Phase III clinical studies that demonstrated its efficacy and safety in lowering blood sugar, reducing weight, and improving metabolic indicators over 52 weeks [2] - The CEO of Xianweida emphasized that the approval marks a significant milestone for Chinese pharmaceutical companies in the field of metabolic diseases and aims to leverage this achievement to further innovate and improve diabetes treatment in China [2]